The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DAWN | -39.57% | N/A | N/A | -68% |
| S&P | +12.66% | +85.37% | +13.13% | +63% |
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $39.80M | -57.6% |
| Gross Profit | $35.32M | -61.7% |
| Gross Margin | 88.74% | -9.6% |
| Market Cap | $722.15M | -40.9% |
| Market Cap / Employee | $3.92M | 0.0% |
| Employees | 184 | 5.7% |
| Net Income | -$19.73M | -153.3% |
| EBITDA | -$23.31M | -176.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $43.28M | -89.8% |
| Accounts Receivable | $16.70M | 92.0% |
| Inventory | 7.1 | 158.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.73M | 7.6% |
| Short Term Debt | $0.16M | 109.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -27.23% | -10.6% |
| Return On Invested Capital | -49.60% | 9.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.81M | -111.6% |
| Operating Free Cash Flow | -$5.81M | -111.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.30 | 1.59 | 1.37 | 1.57 | -60.65% |
| Price to Sales | 9.77 | 5.03 | 3.57 | 5.45 | -58.83% |
| Price to Tangible Book Value | 2.37 | 1.65 | 1.44 | 1.64 | -61.15% |
| Enterprise Value to EBITDA | -11.65 | -8.57 | -6.46 | -12.02 | -145.95% |
| Return on Equity | -22.5% | -17.8% | -24.8% | -30.2% | 69.08% |
| Total Debt | $2.60M | $2.92M | $3.00M | $2.89M | 10.63% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
